People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...

FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid ...

The results, which come on the heels of the FDA’s approval of J&J’s esketamine nasal spray Spravato as a monotherapy for ...

Scientists and legislative activists will meet Tuesday night to discuss the current state of the use of psychedelic ...

Little information has emerged about osavampator, a potentially first-in-class drug, since its promising Phase II performance last spring.

The move expands access to the novel mental health treatment, which has shown rapid symptom improvement for the past few ...

The scientific literature has highlighted the role of inflammation in major depressive disorder (MDD), permeating several states of the disease. In chronic ...

At the time, MDMA, also known as the party drug ecstasy, had been outlawed in Australia since 1987, despite research ...

First patient treated in Phase II portion of clinical trial in metastatic prostate cancer at the West Los Angeles Veterans Administration ...

HC Wainwright restated their buy rating on shares of GH Research (NASDAQ:GHRS – Free Report) in a report issued on Monday,Benzinga reports. The firm currently has a $40.00 price target on the stock.